# China NMPA Drug Inspection - The other 10 companies (see attached list for details) - 11 batches of medicines

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/the-other-10-companies-see-attached-list-for-details/487bfae7-ad11-4aaa-a329-d28ed7eecdd3/
Source feed: China

> China NMPA drug inspection for The other 10 companies (see attached list for details) published September 11, 2020. Drug: 11 batches of medicines. On September 11, 2020, the Gansu Provincial Drug Administration, operating under the framework of the National Medical P

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Announcement from Gansu Provincial Drug Administration
- Company Name: The other 10 companies (see attached list for details)
- Publication Date: 2020-09-11
- Drug Name: 11 batches of medicines
- Inspection Finding: The quality of the sampled product did not meet the standard requirements.
- Action Taken: The relevant market supervision and management departments have taken necessary control measures such as sealing and seizing, and have filed or are in the process of filing cases against the units involved in the products in accordance with relevant laws and regulations. The results of the handling will be made public within three months. They will be urged to find out the cause of the problem, formulate and implement rectification measures, and effectively eliminate potential risks.
- Summary: On September 11, 2020, the Gansu Provincial Drug Administration, operating under the framework of the National Medical Products Administration (NMPA), issued a formal quality announcement regarding pharmaceutical non-compliance. Following sampling inspections conducted by the Jiayuguan Municipal Food, Drug and Medical Device Testing Center and other institutions, 12 batches of drugs from 11 different companies were found to have failed mandatory quality standards. One of the primary entities identified in the report is Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd. The violations cited involve failures in physical properties—such as appearance, texture, and odor—as well as issues with identification testing and the accurate determination of active ingredient content. These failures indicate that the drugs did not meet the necessary benchmarks for safety, authenticity, and therapeutic efficacy. In response, regulatory authorities have seized and sealed the substandard products and initiated formal investigations, with results to be made public within three months. Furthermore, local market supervision bureaus have been ordered to increase oversight, requiring the involved companies to investigate the root causes of these failures and implement comprehensive rectification measures to eliminate potential public health risks.

Company: https://www.globalkeysolutions.net/companies/the-other-10-companies-see-attached-list-for-details/fcf51f71-eede-4dbd-aa29-8691972ee674/